bgcolor="#ffffff" align="center" colspan="2" | Conivaptan chemical structure
|
align="center" colspan="2" | N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-
6(1H)-yl)carbonyl)phenyl)-
(1,1'-biphenyl)-2-carboxamide |
CAS number
210101-16-9 | ATC code
not yet available |
| bgcolor="#eeeeee" | Chemical formula | bgcolor="#ddeeff" | CHNO |
| bgcolor="#eeeeee" | Molecular weight | bgcolor="#ddeeff" | 498.583 |
| bgcolor="#eeeeee" | Bioavailability | bgcolor="#ddeeff" | N/A |
| bgcolor="#eeeeee" | Metabolism | bgcolor="#ddeeff" | ? |
| bgcolor="#eeeeee" | Elimination half-life | bgcolor="#ddeeff" | ? |
| bgcolor="#eeeeee" | Excretion | bgcolor="#ddeeff" | ? |
| bgcolor="#eeeeee" | Pregnancy category | bgcolor="#ddeeff" | ? |
| bgcolor="#eeeeee" | Legal status | bgcolor="#ddeeff" | ? |
| bgcolor="#eeeeee" | Routes of administration | bgcolor="#ddeeff" | Intravenous |